Full-Time

Senior Manager or Associate Director

Medical Writing

Confirmed live in the last 24 hours

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops targeted protein degradation therapies

Biotechnology
Healthcare

Senior

Belmont, MA, USA

Category
Technical Writing
Content & Writing
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Google Cloud Platform
PowerPoint/Keynote/Slides
Requirements
  • BS/BA in the life sciences or related field and at least 5 years of clinical regulatory writing in biotech/biopharma
  • Demonstrated successful experience as a lead writer for clinical protocols, IBs, CSRs, and other clinical and regulatory documents.
  • Strong knowledge of FDA and ICH guidelines, GCP, and applicable US and international regulatory processes related to document preparation. Experience as contributing author for regulatory submissions is desired.
  • Experience with development and implementation of templates, processes, and procedures supporting the MW function.
  • Proficiency in understanding, critically analyzing, and interpreting data and summarizing complex results in a clear, concise, and scientifically accurate manner
  • Well-developed interpersonal skills, with experience interacting with and influencing people, and building strong positive relationships
  • Proficiency in researching and synthesizing scientific literature from various sources.
  • Experience with Microsoft Office Suite (Word, Excel, PowerPoint, and Project); Word toolbars/templates (StartingPoint, TransCelerate); SharePoint; Adobe Acrobat (Standard, Pro); EDMS (Veeva RIM); smartsheet; and PleaseReview
  • Experience with RightFind and reference citation software (EndNote, Reference Manager)
  • Strong project management and time management skills
  • Strong organizational skills and ability to prioritize tasks efficiently
  • Excellent attention to detail and strong written and verbal communication skills
Responsibilities
  • Lead and/or manage the development of clinical and regulatory documents (eg, protocols and amendments, investigator brochures, and clinical study reports) with specific attention to document organization and quality, and adherence to Kymera standards and style
  • Distill scientific data in a clear and concise manner. Ensure consistent key messaging across documents, as appropriate
  • Provide strategic guidance on program/project teams regarding document and timeline development and resource planning
  • Facilitate effective roundtable discussions and record and communicate team-aligned decisions
  • Manage document review process, including scheduling of KOMs, team roundtables, and governance reviews, while implementing best practices
  • Manage external vendors (facilitate onboarding to Kymera standards and systems, review and revise [as needed] deliverables)
  • Lead or participate in process-improvement initiatives (eg, standard MW decks, new or updated SOPs)

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

16%
Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera's recent $275 million public offering provides substantial capital to advance their clinical programs and expand their pipeline.
  • The FDA Fast Track designation for KT-333 could accelerate its development and bring it to market faster, benefiting patients with relapsed/refractory lymphomas.
  • Positive data from ongoing cancer drug trials and the unveiling of KT-294 highlight Kymera's potential for significant breakthroughs in oncology and immunology.

What critics are saying

  • The high costs and long timelines associated with biopharmaceutical R&D could strain Kymera's financial resources despite recent funding.
  • Dependence on partnerships, such as with Sanofi, introduces risks related to collaboration dynamics and milestone achievements.

What makes Kymera Therapeutics unique

  • Kymera Therapeutics leverages its proprietary Pegasus Platform for targeted protein degradation, setting it apart from traditional drug development approaches.
  • Their strategic partnership with Sanofi underscores their credibility and enhances their research capabilities, unlike smaller biotech firms with limited collaborations.
  • Kymera's focus on developing first-in-class therapies for cancer and immune disorders positions them uniquely in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?